A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis

Journal of Crohn's and Colitis

Volumn 4, Issue 3, 2010, Pages 275-282

  Poole, Chris D ^a   Connolly, Mark P ^b   Nielsen, Sandy Kildegaard ^c   Currie, Craig J ^d   Marteau, Philippe ^e  

^a Pharmatelligence   (United Kingdom)

^b Global Market Access Solutions Srl   (Switzerland)

^c Ferring Pharmaceuticals AS   (Denmark)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^e HÔPITAL LARIBOISIÈRE   (France)

Author keywords

EQ 5D; Health state utility; Patient preference; Statistical mapping; Ulcerative colitis

Indexed keywords

MESALAZINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 77955266462     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.11.010     Document Type: Article

References (30)

1. Connolly M.P., Nielsen S.K., Currie C.J., Poole C.D., Travis S.P.L. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohn's Colitis 2009, 3:32-37.
2. Connolly M.P., Nielsen S.K., Currie C.J., Marteau P., Probert C.S.J., Travis S.P.L. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. J Crohn's Colitis 2009, 3:168-174.
3. Sorenson C., Drummond M., Kanavos P. Ensuring value for money in health care: the role of health technology assessment in the European Union. World Health Organization, on behalf of the European Observatory on Health Systems and Policies 2008.
4. Drummond M., McGuire A. Economic evaluation in health care: merging theory with practice 2001, © Oxford University Press.
5. Bassi A., Dodd S., Williamson P., Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004, 53:1471-1478.
6. Hjortswang H., Ström M., Almer S. Health-related quality of life in Swedish patients with ulcerative colitis. Am J Gastroenterol 1998, 93:2203-2211.
7. NICE technology appraisal TA140. Evidence Review Group Report commissioned by the NHS R&D HTA Programme on behalf of NICE. Infliximab for ulcerative colitis (2007). (Accessed 16 August 2009: ). http://www.nice.org.uk/nicemedia/pdf/UlcerativeColitisEvidenceReviewGroupReport.pdf.
8. National Institute for Health and Clinical Excellence (NICE) Guide to the methods of technology appraisal (reference N0515) April 2004, (Accessed 18 August 2009: http://www.nice.org.uk/download.aspx?o=201973).
9. D'Haens G., Sandborn W.J., Feagan B.G., Geboes K., Hanauer S.B., Irvine E.J., et al. A review of activity indices and efficacy points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
10. Sutherland L.R., Martin F., Greer S., Robinson M., Greenberger N., Saibil F., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92:1894-1898.
11. Mortimer D., Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making 2008, 28:66-89.
12. Higgins P.D.R., Schwartz M., Mapili J., Zimmermann E.M. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis. Am J Gastroenterol 2005, 100:355-361.
13. Cooney R.M., Warren B.F., Altman D.G., Abreu M.T., Travis S.P.L. Outcome measurement in clinical trials for ulcerative colitis: towards standardization. Trials 2007, 8:17. 10.1186/1745-6215-8-17.
14. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. EuroQol Group.
15. Marteau P., Probert C.S., Lindgren S., Gassul M., Tan T.G., Dignass A., et al. Combined oral and enema treatment with pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study. Gut 2005, 54:960-965.
16. Dignass A., Bokemeyer B., Adamek H., Mross M., Vinter-Jensen L., Börner N., et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009, 7:762-769.
17. Gray A.M., Rivero-Arias O., Clarke P.M. Estimating the association between SF-12 responses and EQ5D utility values by response mapping. Med Decis Making 2006, 26:18-29.
18. Nagelkerke N.J.D. A note on a general definition of the coefficient of determination. Biometrika 1991, 78:691-692.
19. Walters J.S., Brazier J.E. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003, 1:4. 10.1186/1477-7525-1-4.
20. Baron J.H., Connell A.M., Lennard-Jones J. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964, 1:89-92.
21. Connolly M.P., Poole C.D., Currie C.J., Marteau P., Nielsen S.K. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. Digestion 2009, 80:241-246.
22. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2009, Published Online: 27 July 2009 [Electronic publication ahead of print].
23. Travis S.P.L., Sandborn W.J., Hanauer S.B., Lemann M., Sands B.E., Marteau P., et al. Identification of items to be included in an Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gastroenterology 2009, 136(5). Suppl 1: A-160.
24. Sullivan P.W., Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006, 26:410-420.
25. Dobrez D., Cella D., Pickard A.S., Lai J.-S., Nickolov A. Estimation of patient preference-based utility weights from the functional assessment of cancer therapy-general. Value Health 2007, 10:266-272.
26. UCLA Academic Technology Services FAQ: what are pseudo R-squareds? 2009, (Access 05 September 2009: http://www.ats.ucla.edu/stat/mult_pkg/faq/general/Psuedo_RSquareds.htm).
27. Franks P., Lubetkin E.I., Gold M.E., Tancredi D.J., Jia H. Mapping the SF-12 to the EuroQol EQ-5D index in a national US sample. Med Decis Making 2004, 24:247-254.
28. Sullivan P.W., Lawrence W.F., Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005, 43:736-749.
29. Grootendorst P., Feeny D., Furlong W. Health Utilities Index Mark 3: evidence of construct validity for stroke and arthritis in a population health survey. Med Care 2000, 38:290-299.
30. Nagelkerke N. A note on a general definition of the coefficient of determination. Biometrika 1991, 78(3):691-692.